New Delhi: Tata Consultancy Services (TCS) has collaborated with Dassault Systems via its Living Heart Project. This project unifies an ecosystem of cardiovascular researchers, medical device developers, educators, practicing cardiologists and regulatory agencies including US FDA, to develop and validate realistic digital human heart simulations.
This project will use heart simulations as digital evidence with the aim to approve new cardiovascular devices. This also includes conducting in-silico clinical trials (also known as virtual or computer simulations of clinical trials), which will potentially reduce the current reliance on animal testing and traditional human trials.
As an industry partner, TCS will be weighing in on its domain and technological expertise. It will also rely on the Digital BioTwin of the heart, an innovative computational model crafted by the researchers of TCS. This model helps with the investigation of specific human organ functions through remote and non-invasive methods, thereby providing an insight into human factors and their interactions on a spatial scale.
TCS has also been working on similar Digital BioTwins for other organs like the skin, nose and the colon. Its collaborative plans with Dassault Systems, and other stakeholders, will focus on critical organs and developing their Virtual Human Twin, with the aim of advancing in the field of medical science.
Announcing the partnership, Steve Levine, Senior Director, Virtual Human Modelling, Dassault Systems and founder of The Living Heart Project said, “This collaboration demonstrates our shared commitment to leveraging the virtual world for the advancement of medical science and patient care.”
Sharing the same enthusiasm, Vikram Karakoti, Global Head, Life Sciences Business, Tata Consultancy Services, said, “TCS is excited to be a part of the Living Heart initiative, and to collaborate in creating a pathbreaking digital simulation of the human heart that can enrich our understanding of the cardiac function and provide insights for novel cardiac treatments and new product development for the med-tech and pharma sectors.”